Latham & Watkins advises Starry Group Holdings on uncontested plan of reorganization. Starry Group Holdings, Inc., a fixed wireless broadband internet service provider, received confirmation by...
Starry Group Holdings’ Plan of Reorganization
Vaxcyte’s $500 Million Public Offering
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
Virgin Orbit’s Voluntary Chapter 11
Virgin Orbit is represented by Latham & Watkins as restructuring counsel, and Young Conaway Stargatt & Taylor as local restructuring counsel. Virgin Group is represented by...
Revolution Medicines’ $345 Million Common Stock Public Offering
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
Extensiv’s $80 Million Senior Secured Loan
Latham & Watkins represented Extensiv in the transaction. Runway Growth Capital LLC, a leading provider of growth loans to both venture and non-venture-backed companies seeking an...
Bending Spoons’ Acquisition of Evernote
Latham & Watkins represented Evernote in the transaction. Willkie advised Bending Spoons. Bending Spoons, a leading European technology company, has announced an agreement to acquire Evernote,...
Merck’s $1.35 Billion Acquisition of Imago BioSciences, Inc.
Goodwin Procter advised Centerview Partners on the deal, Latham & Watkins represented Imago BioSciences, Gibson Dunn & Crutcher advised Merck. Merck (NYSE: MRK) and Imago BioSciences, Inc....
Vaxcyte’s $690 Million Public Offering
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
Centricus’ Acquisition of Majority Stake in SK Global Entertainment
Latham & Watkins represented Centricus in the transaction. Centricus, the London-based global investment firm, has acquired a majority stake in SK Global Entertainment, a leading independent...
IDEAYA Biosciences’ $80 Million Common Stock Offering
Latham & Watkins represented IDEAYA, while Davis Polk advised the representatives of the several underwriters in the offering. IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced the pricing of an...
Colonnade Acquisition Corp. II’s Business Combination with Plastiq
White & Case represented Colonnade, while Latham & Watkins represented Plastiq in the transaction. Colonnade Acquisition Corp. II, a special purpose acquisition company (NYSE: CLAA), announced...
Revolution Medicines’ $230 Million Shares Offering
Latham & Watkins represented Revolution Medicines, while Davis Polk advised the underwriters in the offering. Revolution Medicines, Inc. (Nasdaq: RVMD), has announced the pricing of its underwritten...